BlackRock, Inc. 13D and 13G filings for Atossa Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-07-16 7:02 pm Sale | 2025-06-30 | 13G | Atossa Therapeutics, Inc. ATOS | BlackRock Inc. BLK | 2,094,891 1.600% | -7,572,724 (-78.33%) | Filing |
| 2024-11-08 2:17 pm Unchanged | 2024-09-30 | 13G | Atossa Therapeutics, Inc. ATOS | BlackRock Inc. BLK | 9,667,615 7.700% | 0 (Unchanged) | Filing |
| 2024-10-22 3:24 pm Purchase | 2024-09-30 | 13G | Atossa Therapeutics, Inc. ATOS | BlackRock Inc. BLK | 9,667,615 7.700% | 6,078,932 (+169.39%) | Filing |
| 2022-07-08 4:57 pm Sale | 2022-06-30 | 13G | Atossa Therapeutics, Inc. ATOS | BlackRock Inc. BLK | 3,588,683 2.800% | -5,950,910 (-62.38%) | Filing |
| 2022-02-04 4:12 pm Purchase | 2021-12-31 | 13G | Atossa Therapeutics, Inc. ATOS | BlackRock Inc. BLK | 9,539,593 7.500% | 9,539,593 (New Position) | Filing |